Valeant — Could this be the Pharmaceutical Enron ?

,

Citron Publishes the Smoking Gun!!

Price Target lowered to $50

Just four days ago in the world of Valeant, no one had ever heard of Philidor RX.  Recent concerns about the company focused on its unsavory business practices of massive price raises on pharmaceuticals acquired in a rapid succession of acquisitions, while slashing research and development.  But no one had discussed how these drugs were distributed….until this week.

Now Valeant has made new disclosures regarding its distribution channel, and they’ve led the company into a web of deception that … you have to read for yourselves.

For the Rest of the Story, Click Here: 

 

TWOU — For-Profit Education with an “F” in Investability

,

Not Investable — Short Term Price Target $14 ·       

 

2U (NASDAQ:TWOU):
It’s NOT really an SaaS company.  

 

In reality, it is a for-profit outsourced online degree provider founded almost eight years ago, yet still generates ~85% of revenues from only 4 clients.

  • ·        Stock irrationally doubled due to economically inconsequential and highly controversial Yale deal that was denied accreditation on first try
  • ·        2U’s addressable market is tiny, there are dozens of competitors, and its contract economics are unattractive
  • ·        Insider selling and recent capital raise suggest that management thinks stock is overvalued and likely to keep burning cash for next several years
  • ·        Current valuation insane even when benched against actual SaaS companies … ~67%+ downside from current levels.  

For the Rest of the Story You Won’t Read Anywhere Else, Click Here

 

Citron Research Exposes the Information that Congress Will Find if it Subpoenas Valeant

,

Valeant's Business Model is Broken: 
Stock is Too Dangerous to Own:  Short Term Price Target – $125

 

Over the past two weeks, shares of Valeant (NYSE:VRX) took a steep decline over concerns of price gouging that was recently expressed by Presidential hopeful Senator Bernie Sanders.  In his plea for a subpoena of Valeant Sen. Sanders would like to see all communication regarding the price hikes and the reasons behind them. 

Look no further Senator — Citron has done the work.

Over the past two weeks, shares of Valeant took a steep decline over concerns of price gouging that was recently expressed by Presidential hopeful Senator Bernie Sanders.  In his plea for a subpoena of Valeant Sen. Sanders would like to see all communication regarding the price hikes and the reasons behind them.  Look no further Senator — Citron has done the work.

Investors, Politicians, and Concerned Citizens must note that  Valeant raised the prices on the two key heart drugs in question the very next day after they acquired them just to cover up for a bad quarter

Here's the proof — all done without wasting taxpayer money on a hearing.  

For the Rest of the Story You Won't Read Anywhere Else, Click Here